Abacus Life(US:ABL)2025-08-07 21:00Financial Performance - Q2 2025 - Total revenue nearly doubled, reaching $56.2 million compared to $29.1 million in the prior-year period, representing a 93% increase[54] - Adjusted Net Income increased to $21.9 million, compared to $11.7 million, and Adjusted EBITDA increased to $31.5 million, compared to $16.7 million in the prior-year period[54] - GAAP Net Income attributable to shareholders was $17.6 million, compared to $0.7 million in the prior-year period[54] - Assets Under Management (AUM) reached $3.3 billion[17,56] Growth & Capital Deployment - Capital deployed for policy purchases in Q2 2025 amounted to $121.8 million[31,56] - Longevity Funds attracted $123.1 million in capital inflows for the quarter, with the ETFs seeing a +9% increase in growth in AUM compared to the prior quarter[54] - Year-over-year growth in capital deployed totaled $142 million, representing a 16% increase[19] ABL Tech - Mortality Tracking - ABL Tech's mortality tracking system now covers 2,033,198 lives in Q2 2025[46] - ABL Tech experienced a 17x year-over-year increase in lives tracked[44] FY 2025 Guidance - The company raised its Adjusted Net Income guidance for FY 2025 to a range of $74 million to $80 million, implying a +59% to +72% year-over-year change[58]